We are live on
!
Find out more
ARTA
A.R.T. Advisors Portfolio holdings
AUM
$1.79M
1-Year Est. Return
57.47%
This Fund
S&P 500
This Quarter
Est. Return
+6.36%
1 Year Est. Return
+57.47%
3 Year Est. Return
+81.79%
5 Year Est. Return
+178.88%
10 Year Est. Return
–
AUM
$2.26B
AUM Growth
+$299M
(+15%)
Cap. Flow
+$214M
Cap. Flow
% of AUM
9.45%
Top 10 Holdings %
Top 10 Hldgs %
6.6%
Holding
1,916
New
614
Increased
388
Reduced
316
Closed
591
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IBM
IBM
|
+$16.7M |
| 2 |
Netflix
NFLX
|
+$14.1M |
| 3 |
US Bancorp
USB
|
+$12.4M |
| 4 |
GE Aerospace
GE
|
+$11.7M |
| 5 |
Charter Communications
CHTR
|
+$11.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$23M |
| 2 |
AbbVie
ABBV
|
+$18.8M |
| 3 |
Intuit
INTU
|
+$13.1M |
| 4 |
Texas Instruments
TXN
|
+$12.6M |
| 5 |
Booking.com
BKNG
|
+$10.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 14.57% |
| 2 | Industrials | 13.56% |
| 3 | Technology | 13.35% |
| 4 | Healthcare | 13.31% |
| 5 | Financials | 12.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Fortress Biotech
FBIO
$109M
| $103K | ﹤0.01% |
+1,727
| New | +$102K |
|
|
AENZ
1252
DELISTED
Aenza S.A.A.
AENZ
| $103K | ﹤0.01% |
12,092
+6,714
| +125% | +$76.1K |
|
|
ACET
1253
DELISTED
Aceto Corp
ACET
| $103K | ﹤0.01% |
+10,063
| New | +$106K |
|
|
XRN
1254
Chiron Real Estate Inc
XRN
$540M
| $101K | ﹤0.01% |
+2,485
| New | +$111K |
|
1255
GeoPark
GPRK
$615M
| $101K | ﹤0.01% |
10,264
-11,128
| -52% | -$98.9K |
|
1256
Kodak
KODK
$788M
| $101K | ﹤0.01% |
32,716
+17,200
| +111% | +$79.5K |
|
1257
XBiotech
XBIT
$68.9M
| $99K | ﹤0.01% |
25,293
-15,533
| -38% | -$65.4K |
|
1258
Townsquare Media
TSQ
$106M
| $97K | ﹤0.01% |
+12,681
| New | +$111K |
|
|
AGRX
1259
DELISTED
Agile Therapeutics
AGRX
| $97K | ﹤0.01% |
18
+10
| +125% | +$93.1K |
|
|
ARC
1260
DELISTED
ARC Document Solutions, Inc.
ARC
| $97K | ﹤0.01% |
38,141
+22,021
| +137% | +$72.5K |
|
1261
ICL Group
ICL
$6.65B
| $96K | ﹤0.01% |
+23,908
| New | +$99.3K |
|
|
ATXS
1262
DELISTED
Astria Therapeutics
ATXS
| $94K | ﹤0.01% |
1,057
+261
| +33% | +$30.7K |
|
1263
CPI Card Group
PMTS
$235M
| $94K | ﹤0.01% |
25,656
+1,341
| +6% | +$6.57K |
|
|
NXEO
1264
DELISTED
Nexeo Solutions, Inc. Common Stock
NXEO
| $94K | ﹤0.01% |
+10,439
| New | +$82.5K |
|
1265
eGain
EGAN
$187M
| $93K | ﹤0.01% |
+17,719
| New | +$65.3K |
|
|
DRD
1266
DRDGold
DRD
$1.82B
| $89K | ﹤0.01% |
+27,376
| New | +$93.9K |
|
1267
Alto Ingredients
ALTO
$349M
| $87K | ﹤0.01% |
+19,199
| New | +$91K |
|
1268
Veracyte
VCYT
$4.44B
| $87K | ﹤0.01% |
+13,370
| New | +$99.4K |
|
1269
Enel Chile
ENIC
$6.05B
| $86K | ﹤0.01% |
+15,246
| New | +$87K |
|
|
ANW
1270
DELISTED
Aegean Marine Petroleum Network
ANW
| $86K | ﹤0.01% |
20,033
-140,866
| -88% | -$594K |
|
1271
BioCryst Pharmaceuticals
BCRX
$2.43B
| $80K | ﹤0.01% |
16,452
-239,214
| -94% | -$1.16M |
|
1272
Aegon
AEG
$13.5B
| $78K | ﹤0.01% |
15,265
-127,147
| -89% | -$620K |
|
|
GV
1273
DELISTED
Goldfield Corporation
GV
| $78K | ﹤0.01% |
+16,102
| New | +$82.2K |
|
|
IOTS
1274
DELISTED
Adesto Technologies Corp
IOTS
| $78K | ﹤0.01% |
+12,237
| New | +$92.8K |
|
|
SHOS
1275
DELISTED
Sears Hometown and Outlet Stores, Inc.
SHOS
| $76K | ﹤0.01% |
+29,299
| New | +$55.9K |
|
Similar funds
MA
FFIM
LC
YEPV
AAM
CCM
IR
IFC
A.R.T. Advisors's Q4 2017 Portfolio in Review
As of Q4 2017, A.R.T. Advisors held 1,916 positions worth $2.26B, up 15% from $1.96B the previous quarter. Its ten largest holdings account for 6.6% of the portfolio.
A.R.T. Advisors deployed $214M of net new capital in Q4 2017, opening 614 new positions and adding to 388 existing holdings. Its largest new stake was IBM: 114,615 shares worth $16.8M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 15% of assets, down from 16% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was AbbVie, an estimated $18.8M trimmed.
- A.R.T. Advisors's largest Q4 2017 buy was IBM: 114,615 shares worth $16.8M.
- A.R.T. Advisors added most to Netflix in Q4 2017, an estimated $14.1M increase.
- A.R.T. Advisors's biggest Q4 2017 reduction was AbbVie, cutting an estimated $18.8M.
- A.R.T. Advisors fully exited Celgene Corp in Q4 2017, selling an estimated $23M.
- A.R.T. Advisors's ten largest holdings make up 6.6% of its $2.26B portfolio in Q4 2017.
- A.R.T. Advisors opened 614 new positions and closed 591 in Q4 2017.
- A.R.T. Advisors's portfolio value rose 15% quarter-over-quarter to $2.26B.
Based on A.R.T. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.